Weight-loss drugs have become a serious budget issue for employers. PepsiCo has now decided that the benefit is too expensive to keep.
The email from Express Scripts, the pharmacy benefits unit of Cigna, said workers can still pay for the drugs out of pocket, and that common weight-loss medications now have cash-price options.
These medications, known as GLP-1 drugs, include brands like Wegovy and Zepbound. They curb appetite and lead patients to eat less, which explains both their popularity and their heavy cost to plans.
PepsiCo said in the email that the change keeps its healthcare program "sustainable and affordable for every employee."
When employers drop weight loss coverage, grab the free Always Be Buying E-Book to build wealth on any income
In a Mercer survey, about 6% of large employers had already dropped weight-loss coverage in 2026, and another 5% expect to do the same in 2027.
Cigna's Brian Evanko told investors that GLP-1 prescription growth has slowed. Cigna's drug-benefit business is also seeing fewer employers cover these drugs and slower growth in patient usage.
The financial strain on employers is not just about the direct cost of the medications. The ripple effects extend to other parts of the economy. For instance, households that use these drugs tend to spend less on groceries, as the appetite-suppressing effects reduce overall food consumption.
This shift can affect food and beverage companies, which are already adapting their product lines to cater to health-conscious consumers. Additionally, the decision by PepsiCo, a major player in the snack and beverage industry, highlights how these trends are forcing even the largest corporations to reassess their benefit packages and their business strategies. As more employers follow suit, the pressure on drugmakers to justify pricing and on insurers to negotiate better deals will likely intensify.
This story is bigger than one company's benefits plan. It shows how a single medical trend can raise health costs, change employer decisions, and alter consumer spending at the same time.
For investors, the key question is how long this wave lasts. The same drugs that pushed PepsiCo to cut a benefit are also pushing shoppers to buy fewer snacks. If that behavior becomes permanent, food companies will have to keep changing their product mix to match a healthier, less hungry consumer.
The connection between insurance, prescription use, and shopping behavior is why this trend is being watched beyond human-resources departments. A policy decision by one employer may seem small, but when large companies make similar changes, the effects show up in sales data and benefit costs across the economy.
Employers are now facing a choice between managing current costs and keeping benefits attractive. PepsiCo's decision suggests that, for many companies, the immediate price of covering these drugs outweighs other considerations. That is a signal investors should watch as the next round of health-plan decisions is made.
Benefit changes can disrupt plans, so download the free Always Be Buying E-Book and invest steadily